Akari Therapeutics Seeks Share Restructuring, Warrant Approval

TL;DR

**AKTX is setting up for a massive capital raise and potential dilution, so watch out for future share issuances.**

AI Summary

Akari Therapeutics Plc (AKTX) is holding a General Meeting on December 15, 2025, to address several critical resolutions impacting its share structure and future financing. The company seeks approval for the exercisability of purchase warrants and the issuance of underlying ordinary shares from an October 14, 2025 offering, in compliance with Nasdaq Listing Rule 5635(d). A significant proposal involves a sub-division and re-designation of ordinary shares from USD 0.0001 to USD 0.000000005 each, creating 1,429,517,750,998,477 effectively worthless Deferred Shares of USD 0.000000005 each. This restructuring, while not altering shareholders' proportionate interest or ADS value, aims to facilitate future equity financing by authorizing directors to allot shares up to an aggregate nominal amount of USD 3,000 until June 30, 2030, and to disapply pre-emption rights. The board unanimously recommends voting FOR all resolutions, citing them as being in the best interests of the company and its shareholders.

Why It Matters

This DEF 14A filing is crucial for Akari Therapeutics as it outlines a significant corporate restructuring designed to enable future capital raises. The proposed share sub-division and re-designation, while not directly impacting current ADS value or proportionate ownership, clears the path for issuing new equity without pre-emption rights, potentially diluting existing shareholders. For investors, understanding these changes is vital to assess future dilution risk and the company's ability to secure necessary funding for its operations and drug development in a competitive biotech landscape. Employees and customers may see increased stability if the company successfully raises capital, but the creation of 'effectively worthless' deferred shares highlights a complex financial maneuver.

Risk Assessment

Risk Level: high — The risk level is high due to the proposed general authorization for directors to allot shares up to an aggregate nominal amount of USD 3,000 until June 30, 2030, and the empowerment to allot equity securities for cash without pre-emption rights (Resolution 2(b) and 2(d)). This could lead to significant shareholder dilution, especially given the current 71,479,461,523 ordinary shares outstanding as of November 14, 2025, and the creation of 1,429,517,750,998,477 Deferred Shares.

Analyst Insight

Investors should carefully consider the potential for significant future dilution from the proposed share allotment and pre-emption rights waiver. Monitor subsequent filings for details on new equity offerings and their impact on share price and ownership percentages. Evaluate Akari's long-term financing needs against its current valuation.

Key Numbers

• December 15, 2025 — General Meeting Date (Date for shareholder vote on critical resolutions)
• October 14, 2025 — Securities Offering Date (Date of offering related to warrants requiring approval)
• USD 0.0001 — Current Ordinary Share Nominal Value (Proposed to be sub-divided to USD 0.000000005)
• 1,429,517,750,998,477 — Number of Deferred Shares (Created by the share sub-division, effectively worthless)
• USD 3,000 — Authorized Allotment Nominal Amount (Maximum aggregate nominal amount for new share issuance until June 30, 2030)
• June 30, 2030 — Share Allotment Expiry Date (Period for which directors are authorized to allot shares)
• 71,479,461,523 — Ordinary Shares Outstanding (As of November 14, 2025, carrying one vote each)
• 2,000 — Ordinary Shares per ADS (Conversion ratio for American Depositary Shares)
• December 11, 2025 — Ordinary Shareholder Record Date (Deadline for ordinary shareholders to be registered to vote)
• December 4, 2025 — ADS Proxy Card Deadline (Latest date for Deutsche Bank to receive ADS proxy cards)

Key Players & Entities

• Akari Therapeutics Plc (company) — Registrant
• Abizer Gaslightwala (person) — President and Chief Executive Officer
• Hoyoung Huh, M.D. (person) — Chairman of the Board of Directors
• Deutsche Bank Trust Company Americas (company) — ADS depositary
• Equiniti Limited (company) — Company's registrar
• Nasdaq Listing Rule 5635(d) (regulator) — Rule governing warrant exercisability
• USD 0.0001 (dollar_amount) — Current nominal value of ordinary shares
• USD 0.000000005 (dollar_amount) — New nominal value of ordinary shares and deferred shares
• USD 3,000 (dollar_amount) — Aggregate nominal amount for share allotment authorization
• 71,479,461,523 (dollar_amount) — Ordinary shares issued and outstanding as of November 14, 2025

FAQ

Industry Context

Akari Therapeutics Plc operates in the biotechnology sector, focusing on developing treatments for rare diseases. This industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Companies often rely on equity financing to fund their operations and clinical trials, making share structure and capital-raising flexibility crucial for survival and growth.

Regulatory Implications

The company's reliance on Nasdaq listing rules, specifically Rule 5635(d) concerning shareholder approval for offerings involving the issuance of securities, highlights the importance of regulatory compliance. Failure to adhere to these rules could result in delisting. The proposed share sub-division and authorization for share issuance are designed to ensure continued compliance and facilitate future financing needs.

What Investors Should Do

1. Review the proposed share sub-division and its implications for the nominal value of shares and the creation of deferred shares.
2. Evaluate the proposal to authorize directors to allot shares and disapply pre-emption rights.
3. Confirm voting deadlines for both ordinary shareholders (November 14, 2025 record date) and ADS holders (December 4, 2025 proxy card deadline).
4. Consider the company's stated rationale for these proposals, which is to ensure compliance with Nasdaq rules and facilitate future financing.

Key Dates

• 2025-12-15: General Meeting of Shareholders — Shareholders will vote on critical resolutions including warrant exercisability, share issuance, share sub-division, and authorization for future share allotments and disapplication of pre-emption rights.
• 2025-10-14: Securities Offering — Offering of securities that requires shareholder approval for the exercisability of associated purchase warrants and issuance of underlying ordinary shares.
• 2025-11-14: Ordinary Shareholder Record Date — Establishes the list of ordinary shareholders eligible to vote at the General Meeting.
• 2025-11-17: Mailing of Proxy Materials to Ordinary Shareholders — Distribution of the Notice of General Meeting, Proxy Statement, and proxy card to ordinary shareholders.
• 2025-11-24: Mailing of Proxy Materials to ADS Holders — Distribution of proxy materials to holders of American Depositary Shares.
• 2030-06-30: Share Allotment Expiry Date — The date until which the company's directors are authorized to allot shares up to an aggregate nominal amount of USD 3,000.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that includes a company's annual proxy statement. (This document contains the information being analyzed, detailing proposals for the General Meeting and related corporate actions.)

Ordinary Shares

The basic form of stock that represents ownership in a company and typically carries voting rights. (The company is proposing a sub-division and re-designation of its ordinary shares, impacting their nominal value and creating deferred shares.)

American Depositary Shares (ADSs)

Securities traded in the United States that represent ownership of shares in a foreign company. (The proxy materials are being sent to ADS holders, and the proposed share sub-division is structured to not alter the ADS value.)

Purchase Warrants

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specific price on or before a certain date. (The company is seeking approval for the exercisability of purchase warrants issued in an October 14, 2025 offering.)

Deferred Shares

A class of shares created through a sub-division, typically with minimal or no economic value and limited rights, often used for technical restructuring. (The proposed share sub-division will create a large number of effectively worthless deferred shares (1,429,517,750,998,477) to facilitate future financing.)

Pre-emption Rights

The right of existing shareholders to be offered new shares in proportion to their existing holding before they are offered to others. (The company is seeking to disapply these rights, allowing directors more flexibility in issuing new shares for financing purposes.)

Nominal Value

The face value of a share, often a very small amount, used for accounting purposes and to determine authorized share capital. (The proposed sub-division dramatically reduces the nominal value of ordinary shares from USD 0.0001 to USD 0.000000005.)

General Meeting

A formal meeting of a company's shareholders to vote on important matters. (This is the event where shareholders will vote on the critical proposals outlined in the proxy statement.)

Year-Over-Year Comparison

This filing is a proxy statement for a General Meeting, not an annual report (like a 10-K or 20-F), so direct year-over-year financial metric comparisons are not applicable. The focus is on upcoming corporate actions and shareholder votes, rather than historical financial performance. Key information pertains to the proposed restructuring of share capital and authorization for future financing activities, rather than changes in revenue, net income, or margins from a prior period.

Filing Documents

• formdef14a.htm (DEF 14A) — 1033KB
• def14a_001.jpg (GRAPHIC) — 17KB
• proxy_002.jpg (GRAPHIC) — 135KB
• proxy_001.jpg (GRAPHIC) — 323KB
• 0001493152-25-023911.txt ( ) — 1689KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 DELIVERY OF PROXY MATERIALS 17 ADDITIONAL INFORMATION 17 ANNEX A i AKARI THERAPEUTICS, PLC (Registered in England & Wales, No. 05252842) Registered office: Highdown House, Yeoman Way, Worthing, West Sussex BN99 3HH PROXY INFORMATION CONCERNING PROXY SOLICITATION AND VOTING We have sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the “Board of Directors” or “Board”) of Akari Therapeutics, Plc (referred to herein as the “Company”, “we”, “us” or “our”) is soliciting your proxy to vote at our extraordinary general meeting of shareholders (referred to herein as the “Meeting) to be held at 2.30 p.m. London time (9.30 a.m. Eastern Time), on December 15, 2025, at 75/76 Wimpole Street, London, W1G 9RT. This Proxy Statement summarizes information about the resolutions to be considered at the Meeting and other information you may find useful in determining how to vote. The form of proxy is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews. All costs of solicitation of proxies will be covered by us. We are mailing the Notice of General Meeting, this Proxy Statement, and the proxy card to our ordinary shareholders of record as of November 14, 2025 (being the latest practicable date before the circulation of this document) for the first time on or about November 17, 2025 and to our ADS holders on or about November 24, 2025. In addition, we have provided brokers, dealers, bankers, and their nominees, at our expense, with additional copies of our

View Full Filing

View this DEF 14A filing on SEC EDGAR